Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 1246129, 12 pages
http://dx.doi.org/10.1155/2016/1246129
Research Article

The Serum Expression of Selected miRNAs in Pulmonary Sarcoidosis with/without Löfgren’s Syndrome

1Laboratory of Immunogenomics, Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
2Department of Respiratory Medicine and TBC, Palacky University, Olomouc, Czech Republic
3Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

Received 30 August 2016; Accepted 10 November 2016

Academic Editor: Alex Kleinjan

Copyright © 2016 Eva Novosadova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Online Resource 1: A list of TaqMan assays. ID numbers of TaqMan MicroRNA Assays (Applied Biosystems, CA, USA) are listed with their miRNA sequences.

Online Resource 2: Our OPLS modelling showed significant separation between our sarcoidosis patients and healthy controls. Three miRNAs (miR-21, miR-340 and miR-212) however did not provide a good model to separate our sarcoidosis patients according to the presence/absence of Löfgren’s syndrome.

Online Resource 3: The “Pathways in cancer” was consistently predicted to be affected by both expression profiles that were dysregulated in our patients with/without Löfgren’s syndrome (LS) compared to healthy controls. The “TGF-beta signalling pathway” was predicted to be affected by the cumulative effect of three miRNAs whose serum expressions were dysregulated between our patients with LS and those without LS.

  1. Supplementary Material